Criteria for defining resistance to EGFR-TKIs: Are RECIST appropriate?

Date 01 October 2012
Event ESMO Congress 2012
Session A patient with EGFR mutation who progresses to reversible EGFR TKI: What should we do?
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Egbert Smit
Authors E.F. Smit
  • Dept. Of Pulmonary Diseases, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL